FDA Approved: Amneal’s New Epinephrine for U.S. Hospitals
Amneal secured FDA approval for epinephrine injection USP, 1 mg/mL, in 1 mL single-dose and 30 mL multi-dose vials...
Promising 48-Month Azetukalner Epilepsy Study Data by Xenon
Among adults with focal onset seizures in Xenon’s ongoing X-TOLE open-label extension, monthly median percent reduction in seizure frequency...
RAP-219’s Consistent Clinical Response in Focal Seizures
RAP-219 cut median clinical seizure frequency by 77.8% over eight weeks in a 30-patient Phase 2a study of drug‑resistant...
Cretostimogene Data: Potential Backbone Therapy for NMIBC
High-grade event-free survival in BCG-unresponsive papillary-only NMIBC reached 95.7%, 84.6%, and 80.4% at 3, 6, and 9 months, respectively,...
Pociredir’s Promising Results in Sickle Cell Disease Trial
Mean absolute HbF rose 9.9% at Week 6 in the 20 mg cohort of Fulcrum’s Phase 1b PIONEER study,...
TScan’s Alloha Phase 1 Heme Trial Shows Positive Data
Relapse-free survival favored TSC-101 over standard transplant alone in the Phase 1 ALLOHA study with a hazard ratio of...
BioNTech’s Gotistobart Shows Survival Benefit in Lung Cancer
In the non-pivotal, dose-confirmation stage of the randomized Phase 3 PRESERVE-003 trial in metastatic squamous NSCLC after PD-(L)1 therapy...
Legend Biotech: New Myeloma, Lymphoma CAR-T Data at ASH
Topline data: In triple-class–exposed multiple myeloma patients with three prior lines of therapy from CARTITUDE-1, a single infusion of...
Prelude Therapeutics Presents MPN Program Data at ASH 2025
Preclinical data presented at ASH showed that Prelude Therapeutics’ JAK2V617F-selective JH2 inhibitor PRT12396 inhibited mutant JAK2 signaling while preserving...
EpiEndo’s Pioneering EP395 Clinical Trial for COPD Patients
In a 12-week, randomized, double-blind, placebo-controlled study in stable COPD, EP395 (glasmacinal) reduced sputum neutrophilic inflammation versus placebo, was...